The Latest Breaking News from Cardiology

Annual conference of Interventional Cardiology Council begins

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

A new study by The American College of Cardiology suggests that older breast cancer survivors with cardiometabolic may have little risk factors by restricting food consumption to eight hours during the workday. Full story on Dynamite News:

Workers in the department reported there was a lack of respect displayed by some doctors in the department.

VHS will run a dedicated cardiology OPD block at MMM from May 14

It took 11 years for Vladislav Zimin to complete his training in Russia to become an interventional cardiologist, a specialist who places stents in clogged arteries. After that, he practiced for five years, ultimately becoming head of his Moscow hospital’s cardiology and radiology department.

Tech firm will also use funding to develop its products which are used to monitor cardiology patients

At just 22, doctors told Ksenia Borodin a heart and double-lung transplant is her only option for long-term survival. However, the part-time Brisbane law student, who was born with complex heart problems, says she has never felt like giving up amid a lifetime of "near-death experiences".

The FDA's Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), has provided an interim response to Ardelyx Inc's (NASDAQ:ARDX) second level of appeal of the Complete Response Letter (CRL) for Xphozah.  Ardelyx is seeking approval for Xphozah to control serum phosphorus in adult patients with chronic kidney disease (CKD) on…